KMUP-3 attenuates ventricular remodelling after myocardial infarction through eNOS enhancement and restoration of MMP-9/TIMP-1 balance

British Journal of Pharmacology

Volumn 162, Issue 1, 2011, Pages 126-135

  Liu, Chung Pin ^a,b   Yeh, Jwu Lai ^b   Wu, Bin Nan ^b   Chai, Chee Yin ^b   Chen, Ing Jun ^b   Lai, Wen Ter ^b  

^a YUAN'S GENERAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

endothelial nitric oxide synthase; heart failure; K ATP channel; KMUP 3; matrix metalloproteinase 9; myocardial infarction

Indexed keywords

7 [2 [4 (4 NITROBENZENE)PIPERAZINYL]ETHYL] 1,3 DIMETHYLXANTHINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; N(G) NITROARGININE METHYL ESTER; POTASSIUM CHANNEL STIMULATING AGENT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFICACY; DRUG MECHANISM; FIBROBLAST; HEART FUNCTION; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HUMAN CELL; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; HEMODYNAMICS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE TYPE III; PIPERIDINES; RATS; RATS, WISTAR; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR REMODELING; XANTHINES;

EID: 78650160545     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01024.x     Document Type: Article

References (36)

1. Campbell DL, Stamler JS, Strauss HC, (1996). Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J Gen Physiol 108: 277-293.
2. Chen LL, Zhu TB, Yin H, Huang J, Wang LS, Cao KJ, et al. (2010). Inhibition of MAPK signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through reduction of inflammation. Mol Biol Rep 37: 3067-3072.
3. Creemers EE, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, et al. (2003). Deficiency of TIMP-1 exacerbates LV remodeling after MI in mice. Am J Physiol Heart Circ Physiol 284: H364-H371.
4. Eberhardt W, Beeg T, Beck KF, Walpen S, Gauer S, Böhles H, et al. (2000). Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney Int 57: 59-69.
5. Gurjar MV, Sharma RV, Bhalla RC, (1999). eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol 19: 2871-2877.
6. Halapas A, Zacharoulis A, Theocharis S, Karavidas A, Korres D, Papadopoulos K, et al. (2008). Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute MI. Clin Chem Lab Med 46: 510-516.
7. Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, et al. (2005). G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 11: 305-311.
8. Hellermann JP, Jacobsen SJ, Gersh BJ, Rodeheffer RJ, Reeder GS, Roger VL, (2002). Heart failure after myocardial infarction: a review. Am J Med 113: 324-330.
9. Iwakiri Y, Tsai MH, McCabe TJ, Gratton JP, Fulton D, Groszmann RJ, et al. (2002). Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol 282: H2084-H2090.
10. Iwakura A, Shastry S, Luedemann C, Hamada H, Kawamoto A, Kishore R, et al. (2006). Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation 113: 1605-1614.
11. Jones SP, Greer JJ, Van Haperen R, Duncker DJ, De Crom R, Lefer DJ, (2003). Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci USA 100: 4891-4896.
12. Kloner RA, Rezkalla SH, (2004). Cardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol 44: 276-286.
13. ATP channels activated by conjugated estrogens in the regulation of myocardial and coronary protective effects. Circulation 107: 49-54.
14. Lee TM, Lin MS, Chang NC, (2008). Effect of ATP-sensitive potassium channel agonists on ventricular remodeling in healed rat infarcts. J Am Coll Cardiol 51: 1309-1318.
15. Li GH, Shi Y, Chen Y, Sun M, Sader S, Maekawa Y, et al. (2009). Gelsolin regulates cardiac remodeling after myocardial infarction through DNase I-mediated apoptosis. Circ Res 104: 896-904.
16. Liang JC, Chen HR, Chiu CC, Liou SF, Chen IJ, Yeh JL, (2006). Protective effect of labedipinedilol-A, a novel dihydropyridine-type calcium channel blocker, on myocardial apoptosis in ischemia-reperfusion injury. Life Sci 79: 1248-1256.
17. Lin RJ, Wu BN, Lo YC, An LM, Dai ZK, Lin YT, et al. (2006). A xanthine-based epithelium-dependent airway relaxant KMUP-3 (7-[2-[4-(4- nitrobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine) increases respiratory performance and protects against tumor necrosis factor-alpha-induced tracheal contraction, involving nitric oxide release and expression of cGMP and protein kinase G. J Pharmacol Exp Ther 316: 709-717.
18. Lin TH, Chiu HC, Lee YT, Su HM, Juo SH, Voon WC, et al. (2007). The C-allele of tissue inhibitor of metalloproteinases 2 is associated with increased magnitude of QT dispersion prolongation in elderly Chinese-4-year follow-up study. Clin Chim Acta 386: 87-93.
19. Lin X, Jo H, Ishii TM, Fujita M, Fu M, Tambara K, et al. (2009). Controlled release of matrix metalloproteinase-1 plasmid DNA prevents left ventricular remodeling in chronic myocardial infarction of rats. Circ J 73: 2315-2321.
20. Lincoln TM, Corbin JD, (1978). Purified cyclic GMP-dependent protein kinase catalyzes the phosphorylation of cardiac troponin inhibitory subunit (TN-1). J Biol Chem 253: 337-339.
21. Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kytö V, et al. (2007). Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol 150: 851-861.
22. Nee L, O'Connell S, Nolan S, Ryan MP, McMorrow T, (2008). Nitric oxide involvement in TNF-α and IL-1β-mediated changes in human mesangial cell MMP-9 and TIMP-1. Nephron Exp Nephrol 110: e59-e66.
23. + channels in cardiac muscle. Nature 305: 147-148.
24. Peng XQ, Damarla M, Skirball J, Nonas S, Wang XY, Han EJ, et al. (2010). Protective role of PI3-kinase/Akt/eNOS signaling in mechanical stress through inhibition of p38 mitogen-activated protein kinase in mouse lung. Acta Pharmacol Sin 31: 175-183.
25. Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, et al. (2002). Myocardial protection from ischemia/ reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 54: 549-558.
26. Sia YT, Parker TG, Liu P, Tsoporis JN, Adam A, Rouleau JL, (2002). Improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression. J Am Coll Cardiol 39: 148-156.
27. Spinale FG, Coker ML, Bond BR, Zellner JL, (2000a). Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 46: 225-238.
28. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, et al. (2000b). A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102: 1944-1949.
29. Sundström J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. (2004). Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109: 2850-2856. (Pubitemid 38786446)
30. Takai S, Jin D, Inagaki S, Yamamoto D, Tanaka K, Miyazaki M, (2007). Significance of matrix metalloproteinase-9 in cardiac dysfunction during the very acute phase after myocardial infarction in hamsters. Eur J Pharmacol 572: 57-60.
31. Vandegriff KD, Young MA, Lohman J, Bellelli A, Samaja M, Malavalli A, et al. (2008). CO-MP4, a polyethylene glycol-conjugated haemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats. Br J Pharmacol 154: 1649-1661.
32. Wu BN, Lin RJ, Lin CY, Shen KP, Chiang LC, Chen IJ, (2001). A xanthine-based KMUP-1 with cyclic GMP enhancing and K(+) channels opening activities in rat aortic smooth muscle. Br J Pharmacol 134: 265-274.
33. + channel. J Cardiovasc Pharmacol 465: 600-608.
34. Wu BN, Chen CW, Liou SF, Yeh JL, Chung HH, Chen IJ, (2006). Inhibition of proinflammatory tumor necrosis factor-{alpha}-induced inducible nitric-oxide synthase by xanthine-based 7-[2-[4-(2-chlorobenzene) piperazinyl]ethyl]- 1,3- dimethylxanthine (KMUP-1) and 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1, 3-dimethylxanthine (KMUP-3) in rat trachea: the involvement of soluble guanylate cyclase and protein kinase G. Mol Pharmacol 70: 977-985.
35. Yeh JL, Hsu JH, Wu PJ, Liou SF, Liu CP, Chen IJ, et al. (2010). KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathways. Br J Pharmacol 159: 1151-1160.
36. Yoshimura S, Nishimura Y, Nishiuma T, Yamashita T, Kobayashi K, Yokoyama M, (2006). Overexpression of nitric oxide synthase by the endothelium attenuates bleomycin-induced lung fibrosis and impairs MMP-9/TIMP-1 balance. Respirology 5: 546-556.